References
- Brown M, Goldstein JL. How LDL receptors influence cholesterol and atherosclerosis. Sci. Am. 251,58–66 1984
- Castelli WP. Lipids, risk factors and ischemic heart disease. Atherosclerosis 124(Suppl.), S1—S9 (1996).
- Ross R. Atherosclerosis — an inflammatory disease. N Engl. J. Med. 340,115–126 (1999).
- Brown MS, Goldstein JL. Lipoprotein metabolism in the macrophage: implications for cholesterol deposition in atherosclerosis. Ann. Rev. Biochem. 52, 223–261 (1983).
- Li AC, Glass CK. The macrophage foam cell as a target for therapeutic intervention. Nature Med. 8,1235–1242 (2002).
- Steinbrechner UP, Parthasarathy S, Leake DS et al. Modification of low-density lipoprotein by endothelial cells involves lipid peroxidation and degradation of low-density lipoprotein phospholipids. Proc. Nati Acad. Sci. USA 81,3883–3887 (1984).
- Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 105,1135–1143 (2002).
- Libby P, Aikawa M. Stabilization of atherosclerotic plaques: new mechanisms and clinical targets. Nature Med. 8, 1257–1262 (2002).
- Heart Protection Study Collaboration Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomized placebo-controlled trial. Lancet 360,7–22 (2002).
- Topol EJ. Intensive statin therapy: a sea change in cardiovascular prevention. N Engl. J. Med. 350,1562–1564 (2004).
- Suckling KE. Cholesterol and plasma lipid modifying patents. Exp. Opin. Ther. Patents 8(11), 1415–1424 (1998).
- Pentikäinen MO, Ofirni K, Ala-Korpela M et al. Modified LDL — trigger of atherosclerosis and inflammation in the arterial intima. J. Intern. Med. 247, 359–370 (2000).
- Nissen SE, Tuzcu EM, Schoenhagen P et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. J. Am. Med. Assoc. 291,1071–1080 (2004).
- Cannon CP, Braunwald E, McCabe CH et al. Comparison of intensive and moderate lipid lowering with statins following acute coronary syndrome. N Engl. J. Med. 350,1495–1504 (2004).
- Auer J, Berent R, Weber T, Eber B. Clinical significance of pleiotropic effects of statins: lipid reduction and beyond. Curr. Med. Chem. 9,1831–1850 (2002).
- Cybulsky MI, Iiyama K, Li H et al. A major role for VCAM-1, but not ICAM-1, in early atherosclerosis. J. Clin. Invest. 107,1255–1262 (2001).
- Peter K, Weirich U, Nordt TK et al. Soluble vascular cell adhesion molecule (VCAM)-1 as a potential marker of atherosclerosis. Thromb. Haemost. 82(Suppl.), 38–43 (1999).
- Yli-Herttuala S, Lipton BA, Rosenfeld ME et al. Expression of monocyte chemoattractant protein 1 in macrophage-rich areas of human and rabbit atherosclerotic lesions. Proc. Nati Acad. Sci. USA 88,5252–5256 (1991).
- Cushing SD, Berliner JA, Valente AJ et al. Minimally modified low-density lipoprotein induces monocyte chemotactic protein 1 in human endothelial cells and smooth muscle cells. Proc. Natl Acad. Sci. USA 87,5134–5138 (1990).
- Gu L, Okada Y, Clinton SK et al. Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low-density lipoprotein receptor-deficient mice. Mal. Cell 2, 275–281 (1998).
- Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation 107,363–369 (2003).
- Ridker PM, Rifai N, Clearfield M et al. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl. J. Med. 344,1959–1965 (2001).
- Danesh J, Wheeler JG, Hirschfield GM et al C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N EngL J. Med 350, 1387–1397 (2004).
- Reinhart WH. Fibrinogen — marker or mediator of vascular disease? Vasc. Med 8, 211–216 (2003).
- Mizia-Stec K, Zahorska-Markiewicz B, Mandecki T et al Hyperlipidemias and serum cytokines in patients with coronary artery disease. Acta Cardid 58, 9–15 (2003).
- Shishehbor MH, Hazen SL. Inflammatory and oxidative markers in atherosclerosis: relationship to outcome. Curr. Atheroscler. Rep. 6, 243–250 (2004).
Websites
- Association for Eradication of Heart Attack press release on 5 April 2004: AEHA urges caution when considering the impact of the latest C-reactive protein study www.vp.org (Accessed August 2004)